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ABSTRACT 1 
Word count = 228/250 2 
 3 
Introduction 4 
In the era of biomarker-driven systemic therapy for advanced non-small cell lung cancer 5 
(NSCLC), the role of routine repeated biopsies for decision-making, outside EGFR mutant 6 
disease, remains unproven. We report our centre’s experience of safety and adequacy for 7 
molecular retesting of tumour material obtained from image-guided lung rebiopsies in 8 
NSCLC. 9 
 10 
Methods 11 
We performed a retrospective case-note analysis of patients undergoing image-guided lung 12 
rebiopsies at a single cancer centre between 2011-14. The primary objective was the 13 
pathological success rate. Secondary and exploratory objectives were technical success rate, 14 
histological concordance, molecular adequacy, genotypes identified and complication rate. 15 
 16 
Results 17 
103 patients underwent transthoracic image-guided procedures. 66 rebiopsies in NSCLC 18 
were identified and analysed. Pathological success rate was 87.1%. A high histological 19 
discordance rate was observed (12/52 evaluable cases, 23.1%). Pre-test molecular adequacy 20 
as determined by the lung pathologist was 78.8% (52/66). 51 out of 52 adequate samples 21 
were sent for molecular analysis with a total of 209 genes analysed including EGFR, ALK, 22 
KRAS, BRAF, DDR2, NRAS, ROS1 and RET. Post-genotyping molecular adequacy was 23 
87.1% (182/209). 20 new potentially actionable mutations were identified, with 13/66 (19.7%) 24 
patients commencing new targeted treatment as a result. Overall, rebiopsies informed clinical 25 
decision-making in 63.6%. Rates of complications were pneumothorax 15%, pneumothorax 26 
requiring chest drain 3% and haemoptysis 8%. 27 
 28 
Conclusion 29 
4 
 
We validate the pathological and molecular adequacy rates of rebiopsies and demonstrate 30 
clinical utility in routine decision-making.31 
5 
 
INTRODUCTION 1 
Lung cancer is the commonest cause of cancer related mortality in men and women 2 
worldwide,
1, 2
 with more than 80% classified as non-small cell lung cancer (NSCLC). 3 
Identification of driver somatic aberrations in advanced NSCLC has led to rational 4 
implementation of genotype-directed therapy, with international guidelines recommending 5 
molecular testing
3, 4
 since EGFR and ALK kinase inhibitors have demonstrated marked 6 
superior efficacy over chemotherapy in those harbouring activating EGFR mutations and ALK 7 
rearrangements, respectively, and are licensed for 1
st
 line therapy, alongside ROS1 kinase 8 
inhibitors.
5, 6, 7, 8, 9, 10
 However, multiple mechanisms of acquired resistance to molecular-9 
directed therapy have been identified including emergence of additional somatic mutations 10 
with reduced affinity for drug, for instance the EGFR T790M gatekeeper,
11
 but also other less 11 
common mechanisms such as histological non-concordance
12, 13, 14
 or bypass track activation 12 
e.g. through gene amplification.
15
 13 
 14 
Therapeutic strategies to overcome mechanisms of acquired resistance are being developed, 15 
and in some cases licensed. For example, the EGFR mutation-specific kinase inhibitor 16 
osimertinib is active both against classical activating EGFR mutations (e.g. L858R or exon 19 17 
deletion) and the resistance mutation T790M, resulting in FDA and EMA licenses for NSCLC 18 
progressing on or after first-line EGFR-TKI (afatinib/erlotinib/gefitinib) and with evidence of 19 
T790M.
16, 17
 20 
 21 
Other potentially targetable somatic aberrations have been identified in up to 70% of patients 22 
with adenocarcinoma sub-type NSCLC
18
 and in more than 50% of squamous NSCLC
19
 and a 23 
variety of global efforts are underway to identify and validate the efficacy of genotype-directed 24 
therapy in relapsed NSCLC through the multi-arm multi-agent (MAMA) designed trials, such 25 
as the NCI-MATCH trial (NCT02465060) and the UK National Lung MATRIX Trial 26 
(NCT02664935). Whilst circulating tumour DNA (ctDNA) genotyping is an effective and 27 
validated technology for some alleles (e.g. EGFR-T790M), contingent on clinical setting, the 28 
low specificity of some genotyping technologies coupled with the low ctDNA shedding rate for 29 
M1a NSCLC may limit clinical interpretation. 30 
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 31 
Therefore, repeated biopsies for molecular characterisation purposes may be indicated for 32 
the optimal management of patients with relapsed advanced NSCLC, and are recommended 33 
especially in tumours with oncogene addiction to identify resistance-associated genotypes 34 
and guide therapy choice.
3, 20
 35 
 36 
Image guided percutaneous transthoracic core needle biopsies are a standard diagnostic tool 37 
used to obtain tumour tissue at point of diagnosis or relapse. Safety and tissue diagnostic 38 
yields of biopsies at first diagnosis of lung cancer are well established.
21, 22, 23
 However, data 39 
remain limited on the adequacy of tumour material obtained by repeat image-guided 40 
percutaneous biopsies in order to molecularly characterise tumours for clinical decision 41 
making. Here, we report our centre’s experience of safety and adequacy for molecular testing 42 
of tumour material obtained from image-guided transthoracic rebiopsies in NSCLC patients. 43 
METHODS  1 
This is a retrospective analysis of patients undergoing image-guided lung rebiopsies at a 2 
single cancer centre between 2011 and 2014. Rebiopsy was defined as biopsy after cancer 3 
progression following anti-cancer therapy (any line) or repeated biopsy where initial 4 
histological or molecular analysis was inadequate or incomplete for clinical decision-making. 5 
This study was approved by the local audit committee. 6 
 7 
Patients 8 
Patients were identified through search of electronic patient records for those with diagnosis 9 
of NSCLC undergoing image-guided lung biopsies between November 2011 and April 2014. 10 
Patients with other primary thoracic malignancies (e.g. small cell lung cancer, mesothelioma, 11 
thymic malignancies, carcinoid tumours) were excluded. 12 
 13 
Individual case notes were hand-searched for pre-defined data items including fields on 14 
demography (age, gender, smoking history, pulmonary comorbidities, history of other 15 
malignancies), lung cancer (diagnosis, disease stage, number of previous lines of systemic 16 
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anti-cancer treatment, somatic mutational status at biopsy time), rebiopsy data (biopsy 17 
indication, image guidance mode, number of passes, needle gauge, number of cores 18 
obtained), post-procedure complications (pneumothorax, haemoptysis, hospitalization), 19 
rebiopsy tissue sample (presence/absence of malignancy, histological subtype, molecular 20 
analysis performed, mutations identified, molecular success, molecular failure reasons). A 21 
validated data capture spreadsheet was created and populated by two independent 22 
investigators (NT, SB) who reviewed case-notes, identified and entered data. Disagreements 23 
were reviewed and consensus sought with arbitration by a third reviewer (SP). 24 
 25 
Objectives 26 
Primary objective was to determine the pathological success rate, defined as proportion of 27 
rebiopsy cases confirmed to contain malignant cells (as documented in the pathology 28 
reports). 29 
Secondary and exploratory objectives included: technical success rate; concordance of pre-30 
and post-biopsy histological subtype; adequacy of rebiopsy material for molecular analysis; 31 
number and nature of new mutations identified; and incidence of complications. 32 
 33 
Definitions 34 
Technical success was defined as successful insertion of biopsy needle into target lesion and 35 
cells or lung tissues were present in specimen, as documented in the pathology reports. 36 
Histological concordance was determined by comparison of original histological diagnoses, 37 
as documented in case-notes, with histological diagnoses on rebiopsy specimens, which 38 
were reviewed and classified by a dedicated lung pathologist using the 2015 WHO 39 
classification. Diagnostic biopsies were re-reviewed by a dedicated thoracic pathologist where 40 
possible. Molecular analysis of rebiopsy material was performed as clinically indicated for 41 
individual cases. Adequacy of rebiopsy material for molecular analysis was defined as 42 
minimum 30% viable tumour cells in sample, as assessed by a dedicated thoracic pathologist 43 
as per routine practice. Reasons for inadequacy as reported by the pathologist were identified 44 
by case notes review and grouped into consistent themes. Post-test molecular success rate 45 
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was defined as the proportion of successfully informative individual gene analyses out of the 46 
total number of genes analysed. 47 
 48 
Statistical analysis 49 
Differences in inter-gene failure rates were tested using the chi-square test for comparing 50 
multiple proportions with a significance level of α=0.05, with Bonferroni correction for multiple 51 
pairwise comparisons. The relationship between number of cores (<3 versus ≥3 cores) and 52 
molecular adequacy was tested using the Fisher’s exact test, 53 
 54 
RESULTS 1 
Patients 2 
One hundred and three patients were identified from case-notes searching with a diagnosis of 3 
thoracic malignancy undergoing image-guided percutaneous transthoracic procedures 4 
between November 2011 and April 2014. 7 patients had pleural drain insertion or pleural fluid 5 
aspiration and were excluded from analysis. 16 out of 103 patients underwent an initial 6 
diagnostic biopsy for suspected lung cancer (14 to obtain a histological diagnosis and 2 for 7 
completion of staging at diagnosis), and were excluded from further analysis, as this was an 8 
initial biopsy as opposed to a rebiopsy. 14 patients with a diagnosis of other thoracic 9 
malignancy including 10 mesotheliomas, 2 SCLC, and 2 thymic malignancies, were excluded 10 
from further analysis.  11 
66 patients with NSCLC rebiopsy were included in final analysis. Patient characteristics are 12 
summarised in Table 1.  13 
 14 
Procedures 15 
Mode of image guidance was computed tomography (CT) in 60 out of 66 cases (91%) and 16 
ultrasound (US) in 6 cases (9%). Four patients had a CT-guided chest wall biopsy. All 17 
procedures were performed by an experienced interventional radiologist using dedicated CT-18 
guided biopsy software (i-sequence and i-spiral) on a Somatom Definition Edge CT scanner 19 
(Siemens, Erlangen, Germany). Rapid on-site evaluation (ROSE) was not used for any of the 20 
procedures.  21 
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Although all rebiopsies were considered for molecular analysis, primary indications for 22 
rebiopsy varied. Majority of patients underwent rebiopsy primarily for molecular testing (41/66, 23 
62.1%), including 11 patients for first-time molecular analysis, 13 patients for repeat analysis 24 
due to previous failure, 11 for expanded molecular profiling and 6 for EGFR T790M mutation 25 
detection. In 12 patients documented primary indication for repeat biopsy was histological 26 
confirmation of disease relapse, in 4 patients primary indication was to exclude clinical 27 
suspicion of high grade neuroendocrine transformation, while in 2 patients it was disease 28 
restaging. Seven out of 66 patients had a rebiopsy in the context of a research protocol.  29 
 30 
Technical success was achieved in all 66 patients (100% rate). Mean target lesion size was 31 
40.7mm (95% CI: 35.9–45.5), with mean distance to pleura of 15mm (95% CI: 11.35–18.55). 32 
A range of needle gauge sizes was used, from 14G to 18G, with majority procedures 33 
performed using an 18G needle (86% or 45/52 cases where needle gauge size was 34 
documented). Median number of cores obtained was 3 (range: 1 to 6), in one case reported 35 
as “multiple”, and not documented in 3 cases. Target lesion locations were evenly distributed 36 
between all lobes of the lung (53% in upper and 45% in lower lobes), with one lesion located 37 
in the right middle lobe.  38 
 39 
Pathological findings 40 
Pathological success was achieved in 54 out of all 66 patients (81.8%). In 8 patients no 41 
malignant cells were found in the sample. Presence or absence of malignant cells was non-42 
evaluable in 4 cases, when rebiopsy was performed as part of a research protocol. These 4 43 
cases were not evaluated for histopathology and were therefore excluded from further 44 
analyses. Therefore the pathological success rate for evaluable cases was 54/62 (87.1%).  45 
Histological concordance was evaluable in 52 cases (in 2 out of 54 cases containing 46 
malignant cells histological subtype was not reported on rebiopsy tissue). Concordance of 47 
pre- and post-rebiopsy histological subtype was observed in 40/52 (76.9%). Discordance was 48 
observed in 12 (23.1%) cases as detailed in Table 2. In one case, rebiopsy sample 49 
histopathology was consistent with thymoma, in a patient with known synchronous diagnoses 50 
of NSCLC adenocarcinoma and thymoma. 51 
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 52 
Molecular analysis 53 
Fifty two cases were adequate for further molecular analysis as subjectively determined by 54 
the lung pathologist, resulting in pre-test molecular adequacy of 78.8% of all rebiopsy cases. 55 
2 cases containing malignant cells (pathologically successful) were inadequate for molecular 56 
analysis due to “poor sample quality”. 57 
Molecular analysis was performed in 51/66 patients, resulting in a total number of 209 genes 58 
analysed. In one patient whose rebiopsy sample showed NSCLC with rhabdoid 59 
differentiation, tissue was subjectively adequate for molecular analysis, but molecular testing 60 
was not requested as not clinically indicated.  61 
Genes analysed on at least one occasion were EGFR, ALK, KRAS, NRAS, BRAF, DDR2, 62 
ROS1 and RET. Individual PCR-based gene assays were performed including: cobas 63 
480®(Roche) for EGFR and KRAS mutations, capillary electrophoresis single-strand 64 
conformation analysis (CE-SSCA) for EGFR, BRAF exon 15 mutation and NRAS mutations, 65 
and direct sequencing for BRAF exon 11 and DDR2 as next generation sequencing (NGS) 66 
was not routinely implemented during this period. Fluorescence in situ hybridisation (FISH) 67 
was used to detect ALK and ROS1 rearrangements. 68 
One hundred and eighty two genes out of 209 genes were analysed successfully (evaluable), 69 
with post-test molecular success rate of 87.1% (Figure 1).  70 
There was significant inter-gene variation in molecular failure rates (p=0.005). For instance, 71 
EGFR analysis was performed in 50 and ALK analysis in 40 patients, with molecular failure 72 
rates of 4% and 2.5% respectively, while KRAS was analysed 41 times with a failure rate of 73 
24.4% (p=0.04 and p=0.04, respectively). Rates of molecular success and failure by gene are 74 
shown in Table 3. The observed inter-gene variation in failure rates is likely due to sequential 75 
nature of individual gene tests performed, with less material available for each subsequent 76 
analysis.  77 
 78 
Reason for molecular analysis failure, where recorded, was always poor sample quality. We 79 
explored a possible relationship between number of cores obtained and molecular adequacy 80 
and found no significant difference in molecular failure rates between cases where fewer than 81 
11 
 
3 cores were obtained and those with 3 or more cores (p=0.185). There did not appear to be 82 
any clear links between incidence of molecular test failure and patient characteristics or 83 
technical aspects of rebiopsy. 84 
 85 
Twenty four genetic aberrations were identified, including 20 new previously unknown 86 
potentially targetable mutations including: activating mutations in EGFR in two patients in 87 
whom molecular testing had previously failed (one EGFR exon 19 deletion and one S768I 88 
point mutation); two EGFR T790M acquired resistance mutations; one EGFR primary 89 
resistance mutation (exon 20 deletion). ALK rearrangements were identified in 2 patients. 11 90 
patients were found to have a KRAS mutation, 1 patient had a NRAS Q61L mutation and 1 91 
had a DDR2 mutation. 92 
 93 
Safety 94 
Rate of all complications was 25.7% (17 out of 66 patients). Presence of pneumothorax was 95 
assessed in all patients by post-procedure plain chest radiograph or limited post-procedure 96 
chest computed tomography (CT) and confirmed in 12/66 cases (18.2%). However, only 2 out 97 
of 12 cases required intervention with chest drain insertion (3.0%). Median age of patients 98 
suffering a pneumothorax was similar to that of overall study population (63 (range 37-76) 99 
versus 67 (37-84)). Rate of ex or current smoking was slightly higher in the pneumothorax 100 
group than in the overall population (83.3% vs. 71.2%), but none had a history of significant 101 
pulmonary comorbidities compared with 13% in the overall group.  102 
Haemoptysis was reported in 5 out of 66 cases (7.6%), and not recorded in 2 patients. All 103 
cases were categorised as mild haemoptysis (<30ml over 24hrs) not requiring further 104 
intervention. 2 patients (3.0%) required prolonged hospitalisation post-procedure (>48 hours) 105 
for management of pneumothorax requiring chest drain insertion. Three patients required a 106 
prolonged admission for unrelated reasons. 107 
 108 
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Post-rebiopsy clinical outcomes 109 
We extracted data on post-rebiopsy clinical treatment pathways, to explore the ways in which 110 
rebiopsy affected clinical decision-making. This data is summarised in Table 4. In 42 out of 66 111 
patients (63.6%), rebiopsy had a direct impact on the choice of subsequent treatment, 112 
including 13 (19.7%) who commenced licensed targeted therapies for newly identified 113 
somatic mutations (7, 54% in clinical trial setting) or histology-specific chemotherapy. Four 114 
patients (6%) were too unwell for further systemic therapy following rebiopsy.  115 
 116 
13 
 
DISCUSSION 1 
 2 
We report a retrospective study of adequacy of image-guided transthoracic rebiopsies in 66 3 
patients in terms of safety, technical success rates, and adequacy for pathological and 4 
molecular analysis.  5 
 6 
With 100% technological success rate, 87.1% pathological adequacy and 78.8% molecular 7 
adequacy as subjectively assessed by a lung pathologist, we show that image guided lung 8 
rebiopsies are feasible and can yield tissue adequate for analysis of multiple biomarkers in 9 
the setting of standard clinical practice. We report rates of pneumothorax (18%), chest drain 10 
insertion (3%) and mild haemoptysis (8%) which are similar to those previously reported in 11 
large series of percutaneous transthoracic biopsies in primary diagnostic setting
24, 25, 26, 27 
and 12 
therefore conclude that rebiopsy is not at any increased risk compared to primary biopsies. 13 
 14 
We observed a relatively high rate of histological discordance of 23% between rebiopsy 15 
material and prior diagnostic biopsies. In cases where histological discrepancy was observed, 16 
initial diagnostic biopsies were re-reviewed where available to explore possible causes for the 17 
differences. In two cases where squamous cell carcinoma at initial biopsy was reclassified as 18 
adenocarcinoma on rebiopsy, and where diagnostic biopsy material was available for review, 19 
rebiopsy tumour material showed some features of overlap between adenocarcinoma and 20 
squamous cell carcinoma. The discordance between biopsies may therefore reflect sampling 21 
of different components of the same tumour with both adenocarcinoma and squamous cell 22 
carcinoma features. Another possible explanation for the observed differences may be 23 
sampling bias, with patients whose initial samples were inadequate for optimal histological 24 
assessment and diagnosis selected for rebiopsy, leading to higher rates of histological 25 
discordance in our cohort (e.g. 3 instances of NSCLC NOS were reclassified as squamous 26 
cell carcinoma). 27 
 28 
Overall 182 of 209 (87.1%) individual gene tests were performed successfully in 51 patients. 29 
Molecular success rates varied significantly between individual gene assays. EGFR testing 30 
14 
 
was completed successfully in 48 out of 50 cases (96%), in line with rates reported in several 31 
previous studies of adequacy of rebiopsy tissue for EGFR testing.
14, 28, 29, 30, 31
 Two 32 
prospective studies of rebiopsies in 121
30
 and 162
14
 patients with acquired resistance to 33 
EGFR-TKIs reported rates of 86% and 95.6% respectively. Another recent prospective study 34 
enrolled 24 EGFR mutant patients commencing afatinib therapy with a view to rebiopsy for 35 
EGFR T790M analysis at progression. Out of 23 patients who developed progressive 36 
disease, only 14 completed a rebiopsy, with 11 samples (78.6%) sufficient for molecular 37 
analysis.
31
 38 
 39 
Most studies of rebiopsies have focused on mechanisms of acquired resistance to EGFR-TKI 40 
and in particular detection of T790M mutation, and few studies have evaluated adequacy for 41 
multiple biomarker testing on rebiopsy tissue outside of this context.
32, 33, 34
 Tam et al have 42 
reported a retrospective analysis of adequacy of percutaneous transthoracic core needle 43 
biopsies for the evaluation of multiple molecular biomarkers within the context of the 44 
genotype-directed BATTLE trial.
33
 170 biopsies were performed in 151 NSCLC patients 45 
screened for the trial. Specimens of 82.9% of patients were found to have adequate tumour 46 
tissue for analysis of 11 different biomarkers within EGFR, KRAS, BRAF, VEGFR, RXR and 47 
Cyclin D genes. Pneumothorax and chest tube insertion rates were 15.3% and 9.4%, 48 
respectively. In our study, rates of pre-test (87.1%) and post-test molecular adequacy (78.8%) 49 
are similar to those reported in the BATTLE trial despite our relatively unselected patient 50 
cohort in the setting of standard clinical practice. 51 
 52 
The main limitation of this study is that this is a retrospective observational study based on 53 
clinical experience of a single oncology centre. As a tertiary referral centre and an institution 54 
with well-established infrastructure and experience in this area, our experience may not be 55 
representative of the patient profile and resources available in other community-based 56 
centres. Secondly, the discrepancy between subjective pathologist assessed pre-test 57 
molecular adequacy and post-test molecular success rate has been difficult to explore in 58 
absence of complete data on reasons for test failure. Thirdly, incomplete data on technical 59 
aspects of each procedure precluded analysis of potential relationship between incidence of 60 
15 
 
molecular analysis failure and the way procedures were performed, which would help define 61 
optimal conditions to obtain adequate tissue samples. Finally, instead of single-gene tests 62 
performed in parallel or sequentially, many centres have now moved to implementing NGS-63 
based molecular genotyping,
35, 36, 37, 38
 and so the individual molecular success rate at 64 
individual genes may not reflect changes in gene-testing methodologies. 65 
 66 
Choice of optimal treatment and development of treatment strategies in NSCLC are 67 
predicated by tumour histological and molecular characterisation. Repeated molecular 68 
profiling is likely to be required at multiple time points during the treatment pathway, as is 69 
already the case for EGFR T790M mutation detection,
20
 given inter-patient and intra-patient 70 
molecular heterogeneity identified from sequencing studies,
39
 and evolutionary pressures of 71 
molecular selection form targeted therapy in oncogene-addicted NSCLCs. Nevertheless, in a 72 
real world setting, our data has identified the clinical utility and limitations of rebiopsies in 73 
advanced NSCLCs, demonstrating a clinically important utility in decision-making and for 74 
molecular characterization. Improvements in the histological yield and molecular adequacy of 75 
rebiopsies may be achieved by implementation of standardised protocols and algorithms in 76 
radiology departments and laboratories to ensure optimal handling of samples for molecular 77 
analyses as highlighted in the CAP/IASCL/AMP Guideline.
40
 Use of rapid on-site evaluation 78 
(ROSE) of specimens at time of procedure has been shown to improve diagnostic yield, 79 
decrease the need for repeat procedures and facilitate collection of sufficient material for 80 
molecular testing,
41
 although resource considerations are likely to affect wide-spread use of 81 
this technique.   82 
 83 
Validation of circulating tumour DNA (ctDNA) for genotyping is facilitating a less invasive 84 
approach for detection of EGFR T790M at point of progression,
42
 but tissue based verification 85 
remains an important strategy to identify patients suitable for EGFR T790M inhibitors, 86 
especially due to the low sensitivity of some ctDNA testing methods. It is also important to 87 
verify other resistance mechanism such as histological non-concordance and to stratify 88 
patients for other systemic therapies within clinical trials.  In our study rebiopsies produced 89 
clinically relevant information, helping to guide the choice of treatment in nearly two thirds of 90 
16 
 
patients, through identification of new actionable driver and resistance mutations, change in 91 
histological classification, and confirmation or exclusion of recurrent disease. 92 
 93 
Our study provides valuable data on the role and utility of rebiopsy for molecular analysis of 94 
multiple molecular markers in a heterogeneous group of NSCLC patients in the setting of 95 
standard clinical practice. We validate the pathological and molecular adequacy rates of 96 
rebiopsies and demonstrate clinical utility in routine decision making.97 
17 
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TABLES 
 
Demographic variable  No. out of 66 (%) 
Median Age 67 (IQR 60-71)  
Sex   
   Male  35 (53) 
 Female  31 (47) 
Smoking (at time of diagnosis)   
 Ex-smoker  35 (53) 
 Never smoker  18 (27) 
 Active smoker  12 (18) 
 Unknown  1   (2) 
Pulmonary Comorbidities   
   None  57 (86) 
 COPD  5   (7) 
 Previous pulmonary TB  2   (3) 
 Asthma  1   (2) 
 Emphysema  1   (2) 
Other malignancy   
 Yes*  4   (6) 
 No   62 (94) 
Histological subtype at time of biopsy   
 Adenocarcinoma  45 (68) 
 Squamous cell carcinoma  14 (21) 
 Adenosquamous  1   (2) 
 NSCLC NOS  6   (9) 
Stage at diagnosis   
 II    6   (9) 
 III  7   (11) 
24 
 
 IV  53 (80) 
Previous lines of systemic treatment   
     0  16 (24) 
 1  24 (36) 
 2  14 (21) 
 3  7   (11) 
     4  5   (8) 
Mutational status at time of biopsy   
   EGFR          
 
 
 Unknown 37 (56) 
 EGFR WT  20 (30) 
          EGFR mutation present  9   (14) 
   ALK 
 
 
 Unknown 51 (77) 
 No rearrangement 14 (21) 
          Rearrangement present  1   (2) 
Table 1. Patient characteristics 
*Other malignancies: 3 patients had past history of endometrial cancer (1), breast cancer (1) and basal 
cell carcinoma lip (1). 1 patient had a concurrent diagnosis of thymoma.   
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Original histology n Rebiopsy histology Number (%) 
Adenocarcinoma 38 
Adenocarcinoma 
NSCLC NOS  
Poorly differentiated TTF-1 negative ca. 
36 (94.8) 
1 (2.6) 
1 (2.6) 
Squamous cell carcinoma 9 
Squamous cell carcinoma 
Adenocarcinoma 
NSCLC NOS  
Pleomorphic ca. rhabdoid subtype 
3 (33.3) 
4 (44.5) 
1 (11.1) 
1 (11.1) 
NSCLC NOS 4 
NSCLC NOS 
Squamous cell carcinoma 
1 (25.0) 
3 (75.0) 
Adenosquamous carcinoma 1 Adenocarcinoma 1 (100) 
Total* 52 
Concordant 
Discordant 
40 (76.9) 
12 (23.1) 
Table 2. Histological discordance rates 
*Total of 52 cases were evaluable for histological concordance. 14 cases were non-evaluable including: 
8 cases with no malignant cells in sample (pathological fail), 4 cases sent to research laboratory, 2 
cases histological subtype not reported. NOS, not otherwise specified. 
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Gene No. analysed No. failed Wild type 
Mutation/ 
rearrangement 
present 
Failure 
rate 
EGFR 50 2 39 9 4% 
ALK 40 1 37 2 2.5% 
KRAS 41 10 20 11 24.4% 
BRAF Exon 11 27 6 21 0 22.2% 
BRAF Exon 15 40 7 33 0 17.5% 
DDR2 5 1 3 1 20% 
ROS1 3 0 3 0 0% 
RET 2 0 2 0 0% 
NRAS 1 0 0 1 0% 
TOTAL 209 27 158 24 12.9% 
Table 3. Molecular analysis results by gene 
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Post-Rebiopsy Clinical Outcomes No. of patients 
Potentially actionable genetic mutation identified 20 
 Patients started licenced TKI* 6 
Patients entered clinical trial of targeted therapy* 7 
Patients started chemotherapy but potentially eligible for 
future clinical trial* 
4 
Patients too unwell for further systemic therapy  3 
Activating mutation confirmed/no acquired resistance mutation 4 
 Patients switched to chemotherapy 2 
Patients switched to second generation TKI 1 
Patients too unwell for systemic therapy 1 
Mandatory biopsy within research protocol – patients entered clinical trial*  6 
Histological discordance identified – new treatment paradigm* 4 
Histological confirmation of NSCLC recurrence* 12 
  Patients started palliative treatment* 10 
Patients started radical treatment* 2 
NSCLC recurrence ruled out – patients continued surveillance* 3 
Pathological or molecular failure 13 
No actionable mutations identified 4 
Total 66 
Table 4. Rebiopsy outcomes and post-biopsy patient pathways.  
*indicates patients in whom rebiopsy informed subsequent choice of treatment. 
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FIGURE LEGEND 
 
Figure 1. Consort diagram. 
 
